Myriad Genetics downgraded at JMP Securities

As previously reported, JMP Securities downgraded Myriad Genetics to Market Perform from Outperform. The firm's oncologists and ob/gyns survey indicates 40% of BRCA1/BRCA2 testing could migrate to other manufactures within 2 years, almost double the magnitude previously forecast. Additionally, the firm said new reimbursement levels will be an overhang until there is further clarity.

View Comments (0)